SLU-PP-332 Research: Overview, Mechanism & Data

SLU-PP-332 represents a compelling subject in current biochemical research, functioning as an estrogen-related receptor (ERR) agonist. Its mechanism of action involves modulating ERR activity, which is a key area of study in exercise-mimetic and metabolic research. This compound offers a valuable tool for investigators probing complex cellular and systemic responses in various preclinical models.

The profound interest in SLU-PP-332 is evidenced by numerous peer-reviewed publications indexed in prominent scientific databases like PubMed, detailing a wide array of experimental findings. Furthermore, its research significance is underscored by several registered studies on ClinicalTrials.gov, primarily focusing on its mechanistic characterization and potential research applications in preclinical settings, providing a robust foundation for continued scientific inquiry.

Understanding Estrogen-Related Receptors (ERRs) in Research

Estrogen-related receptors (ERRs) constitute a fascinating and extensively studied subfamily within the nuclear receptor superfamily. Despite their nomenclature, ERRs are orphan receptors, meaning their endogenous ligands were initially unknown, and they do not bind traditional estrogens with high affinity. This distinguishes them fundamentally from classical estrogen receptors (ERs), though they share significant structural homology, particularly in their DNA-binding domains. There are three identified ERR isoforms in mammals: ERRα (NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3). These receptors are constitutively active transcription factors, playing critical roles in the regulation of gene expression across a wide array of physiological processes, making them compelling targets for basic and translational research.

The ubiquity and diverse functions of ERRs underpin their significance in various research fields. They are pivotal regulators of cellular energy metabolism, influencing processes such as mitochondrial biogenesis, fatty acid oxidation, and glucose homeostasis. For instance, ERRα is particularly recognized for its role in regulating genes involved in oxidative phosphorylation and mitochondrial function, especially in tissues with high metabolic demand like skeletal muscle and cardiac tissue. ERRγ also contributes significantly to metabolic pathways, often overlapping with or complementing ERRα functions. Research into ERRβ suggests roles in placental development and neurogenesis, highlighting the isoform-specific nuances within the ERR family.

Key Research Areas Involving ERRs

The multifaceted involvement of ERRs makes them central to investigations across several domains. Understanding the specific roles of each ERR isoform and their downstream transcriptional targets provides valuable insights into fundamental biological mechanisms and potential pathways for modulation in research models.

Metabolic Regulation: ERRs are crucial for maintaining energy balance, regulating genes involved in glucose and lipid metabolism, mitochondrial respiration, and thermogenesis. Studies often focus on their impact on metabolic disorders in preclinical models.
Exercise Physiology: The activation of ERRs, particularly ERRα, is strongly linked to adaptive responses to exercise, promoting mitochondrial biogenesis and enhancing oxidative capacity in skeletal muscle. Research endeavors explore how ERR modulation can mimic or enhance exercise-induced benefits.
Cellular Growth and Differentiation: ERRs contribute to cell proliferation, differentiation, and tissue development, with ERRβ having notable roles in embryonic development and stem cell fate.
Inflammation and Immunity: Emerging research suggests ERRs may also modulate inflammatory responses and immune cell function, expanding their potential scope as research targets.

Given their foundational roles in cellular energetics and physiological adaptation, ERRs are widely recognized as critical nodes in biological systems. Researchers worldwide are actively exploring the intricacies of ERR signaling pathways to unravel their full potential as targets for mechanistic studies in diverse biological contexts, including exercise-mimetic and metabolic research applications, as further detailed in subsequent sections regarding SLU-PP-332.

SLU-PP-332: Chemical Structure and Classification as an ERR Agonist

SLU-PP-332 is a well-characterized synthetic small molecule specifically developed for research applications, distinguished by its classification as a potent agonist of Estrogen-Related Receptors (ERRs). While the precise proprietary chemical structure itself is complex and defined, its functional classification as an ERR agonist is paramount to understanding its utility in research. As an agonist, SLU-PP-332 functions by binding to and activating ERRα, ERRβ, and ERRγ, thereby mimicking and enhancing the endogenous transcriptional activity typically associated with these receptors. This mechanism allows researchers to specifically probe the downstream effects of ERR activation in various experimental models without direct interference from traditional estrogen signaling pathways, which are often involved in more complex regulatory networks.

The development of selective ERR agonists like SLU-PP-332 represents a significant advancement in the study of ERR biology. Prior to the availability of such compounds, elucidating the specific roles of ERRs, particularly given their ‘orphan’ status, was challenging. SLU-PP-332’s ability to directly engage and activate these receptors with high affinity and selectivity provides a powerful tool for dissecting the intricate signaling cascades regulated by ERRs. Its classification as an ERR agonist is supported by extensive biochemical and cellular studies demonstrating its capacity to induce ERR-mediated gene expression. This compound serves as an invaluable probe in pharmacological research, enabling precise control over ERR activity in isolated cells, tissues, and preclinical models to understand their physiological and pathophysiological contributions.

Importance of Purity and Characterization for Research-Use-Only Compounds

For a compound like SLU-PP-332, intended strictly for research-use-only, meticulous attention to its chemical structure, purity, and rigorous characterization is critical. High purity is essential to ensure that experimental results accurately reflect the intended agonistic action on ERRs, free from confounding effects of impurities or contaminating substances. Impurities could potentially interact with other biological targets, leading to off-target effects and misinterpretation of data. Therefore, analytical confirmation of identity and purity is a foundational step for any reputable research chemical supplier.

Parameter	Significance for Research Integrity
Chemical Identity	Confirms the compound supplied is indeed SLU-PP-332, preventing misidentification and ensuring reproducibility of studies.
Purity Level	High purity (typically >98-99%) minimizes the presence of other compounds that could confound experimental results or lead to unintended effects.
Stability	Ensures the compound remains effective and intact under recommended storage and handling conditions, preserving its chemical and pharmacological properties over time.
Solubility Profile	Provides essential information for proper preparation of stock solutions and experimental dosing, crucial for consistent and reliable research outcomes.

Researchers relying on compounds like SLU-PP-332 should always verify the supplier’s commitment to quality testing and transparent reporting. Such diligence ensures the reliability and validity of experimental findings in fields ranging from exercise-mimetic research to metabolic studies, where precise modulation of ERR activity is key. Understanding and trusting the chemical integrity of the research tools is paramount for advancing scientific knowledge responsibly.

Mechanism of Action: Agonism of Estrogen-Related Receptors

The mechanism of action for SLU-PP-332 revolves around its ability to function as a direct agonist of Estrogen-Related Receptors (ERRs). Upon introduction into a biological system, SLU-PP-332 diffuses across the cell membrane and binds to the ligand-binding domain (LBD) of the ERR isoforms (ERRα, ERRβ, and ERRγ). Although ERRs were historically considered ‘orphan’ receptors due to a lack of classic endogenous ligands, compounds like SLU-PP-332 effectively occupy the ligand-binding pocket, inducing a conformational change within the receptor protein. This conformational shift is critical, as it reconfigures the receptor to a transcriptionally active state, facilitating the recruitment of co-activator proteins and promoting the dissociation of co-repressors.

The activated ERR-SLU-PP-332 complex then translocates, or is already present, in the nucleus, where it binds to specific DNA sequences known as ERR response elements (ERREs) in the promoter regions of target genes. These ERREs are typically characterized by a common AGGTCA core sequence. The recruitment of co-activators, such as PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha), is a particularly important aspect of ERR agonism. PGC-1α is a master regulator of mitochondrial biogenesis and metabolic gene expression, and its interaction with activated ERRs significantly amplifies the transcriptional output. This intricate interplay between SLU-PP-332, ERRs, and co-activators culminates in the upregulation of genes involved in various metabolic processes, including fatty acid oxidation, mitochondrial respiration, and glucose metabolism. For a more detailed breakdown of this process, researchers may find additional resources at our dedicated mechanism of action page.

ERR Agonism vs. Estrogen Receptor Activation

It is crucial for researchers to understand the distinction between ERR agonism and the activation of classical estrogen receptors (ERs). While ERRs share structural homology with ERs, particularly in their DNA-binding domains, their ligand specificities and physiological roles are distinct. SLU-PP-332 is specifically designed to target ERRs and exhibits minimal to no agonistic activity on ERα or ERβ at research-relevant concentrations. This selectivity is a key feature that makes SLU-PP-332 an invaluable research tool, allowing for the precise investigation of ERR-mediated pathways without confounding effects from estrogenic signaling.

The selective agonism of ERRs by SLU-PP-332 allows for the disentanglement of ERR-specific functions from the broader estrogenic signaling network. This targeted approach is particularly beneficial in research exploring metabolic adaptations, exercise physiology, and cellular energy homeostasis, where ERRs play prominent but distinct roles. By activating ERRs, SLU-PP-332 can induce gene expression profiles that promote mitochondrial growth, increase oxidative capacity, and enhance lipid catabolism, effectively mimicking some of the metabolic benefits observed in response to physical activity in research models. This precise mechanistic understanding underscores the utility of SLU-PP-332 as a high-fidelity tool for advanced mechanistic studies.

Investigating SLU-PP-332 in Exercise-Mimetic Research Models

Estrogen-related receptors (ERRs) are critical orphan nuclear receptors that play pivotal roles in regulating cellular energy metabolism, particularly within tissues with high energetic demands such as skeletal muscle. SLU-PP-332, classified as an ERR agonist, provides researchers with a valuable chemical probe to investigate the intricate pathways governing metabolic adaptation in response to cellular energetic stress. Research in exercise-mimetic models seeks to understand the molecular and physiological adaptations typically observed with physical activity, often by identifying pharmacological tools that can modulate these pathways. SLU-PP-332’s agonistic activity at ERR sites makes it a compelling subject for exploring these cellular responses, potentially revealing fundamental insights into mitochondrial biogenesis, fuel utilization, and muscle plasticity.

The mechanism by which SLU-PP-332 exerts its effects in exercise-mimetic research models is centered around the activation of ERRs, notably ERRα, which is a key transcriptional regulator. Activation of ERRα is known to orchestrate the expression of genes involved in mitochondrial oxidative phosphorylation, fatty acid oxidation, and the master regulator of mitochondrial biogenesis, PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha). By selectively engaging these pathways, SLU-PP-332 can be utilized in research to mimic or potentiate certain metabolic shifts characteristic of endurance exercise, such as increased mitochondrial content and enhanced capacity for lipid metabolism. Understanding these precise molecular interactions is crucial for dissecting the complex signaling networks that govern exercise adaptation. For a detailed exploration of the molecular interactions, please refer to our dedicated page on the Mechanism of Action: Agonism of Estrogen-Related Receptors.

Preclinical investigations into SLU-PP-332 in exercise-mimetic contexts often employ a range of *in vitro* and *in vivo* models. *In vitro*, researchers frequently utilize muscle cell lines, such as C2C12 myotubes, to study gene expression changes, mitochondrial respiration, and substrate utilization in response to SLU-PP-332 administration. These models allow for precise control over experimental conditions and the direct measurement of cellular parameters. *In vivo* studies commonly involve rodent models, where SLU-PP-332 is administered to mice or rats, often in conjunction with exercise regimens (e.g., forced treadmill running, voluntary wheel running) or under sedentary conditions. These studies aim to observe systemic effects on muscle physiology, metabolic enzyme activity, and markers of endurance capacity, providing a broader physiological context for the cellular findings.

Key research readouts in these studies include the quantification of mRNA and protein levels of ERR target genes (e.g., PGC-1α, NRF1, TFAM, various subunits of the electron transport chain) using techniques such as quantitative PCR and Western blotting. Mitochondrial function is frequently assessed through high-resolution respirometry, measuring oxygen consumption rates in isolated mitochondria or whole cells. *In vivo*, functional assessments may include measurements of running distance, time to exhaustion, or changes in muscle fiber type composition via histological analysis. Collectively, these methodologies provide a comprehensive framework for investigating the potential of SLU-PP-332 as a research tool to deepen our understanding of exercise physiology and metabolic adaptation.

Metabolic Research Applications of SLU-PP-332

Beyond its utility in exercise-mimetic studies, SLU-PP-332 serves as a significant research compound for exploring broader aspects of metabolic regulation. Estrogen-related receptors are known to be intricately involved in maintaining metabolic homeostasis across various tissues, including the liver, adipose tissue, and pancreas, in addition to skeletal muscle. As an ERR agonist, SLU-PP-332 offers a unique opportunity for scientists to perturb and analyze metabolic pathways, contributing to a more profound understanding of how cells and organisms manage energy balance, nutrient partitioning, and overall metabolic health. The compound’s specificity allows for targeted investigations into the ERR signaling axis, disentangling its contributions from other nuclear receptor pathways.

Research applications of SLU-PP-332 frequently focus on its impact on key metabolic processes such as glucose homeostasis, lipid metabolism, and mitochondrial function. Studies may investigate how SLU-PP-332 influences glucose uptake and utilization in various cell types, or its role in regulating hepatic gluconeogenesis and glycogenolysis. In the realm of lipid metabolism, researchers explore its effects on fatty acid oxidation rates, lipogenesis, and triglyceride accumulation within adipose tissue and the liver. Furthermore, given the central role of ERRs in mitochondrial biology, SLU-PP-332 is employed to probe mitochondrial respiratory capacity, ATP production, and overall cellular energy expenditure, including aspects of adaptive thermogenesis in brown adipose tissue.

Researchers utilize SLU-PP-332 to address fundamental questions concerning metabolic dysregulation. For instance, *in vitro* models involving insulin-resistant cell lines or *in vivo* models of diet-induced obesity (DIO) or genetic metabolic disorders can be treated with SLU-PP-332 to observe its effects on markers of insulin sensitivity, glucose tolerance, and lipid profiles. The goal of these investigations is not to develop specific treatments but rather to elucidate the underlying molecular mechanisms and signaling cascades that contribute to metabolic imbalances. By modulating ERR activity with SLU-PP-332, scientists can gain critical insights into the pathophysiology of various metabolic states and identify potential nodes for further mechanistic study.

The integration of SLU-PP-332 into diverse metabolic research paradigms facilitates a holistic view of its physiological impact. Studies may combine metabolic analyses with exercise-mimetic protocols to explore synergistic effects or differentiate specific ERR-mediated metabolic adaptations from general exercise responses. Through rigorous experimental design and comprehensive analytical approaches, investigations using SLU-PP-332 aim to advance the foundational knowledge of energy metabolism, providing a crucial tool for dissecting the complex interplay between cellular signaling, tissue function, and whole-organism metabolic regulation.

Preclinical Models and Methodologies in SLU-PP-332 Studies

Preclinical research on SLU-PP-332 relies on a robust array of experimental models and methodologies designed to meticulously characterize its biological effects as an ERR agonist. These investigations span various levels of biological complexity, including *in vitro* (cell-based), *ex vivo* (tissue-based), and *in vivo* (whole-organism) studies. The selection of the appropriate model is paramount and is dictated by the specific research question being addressed, aiming to provide maximal mechanistic insight while adhering to ethical research standards. A rigorous approach to preclinical methodology is essential for generating reliable and reproducible data that contribute meaningfully to the scientific understanding of ERR biology.

In Vitro Methodologies

Cell culture models are foundational for initial investigations into SLU-PP-332. Researchers commonly employ a variety of cell lines to assess specific cellular responses.

Muscle Cells: C2C12 myoblasts differentiated into myotubes are frequently used to study mitochondrial biogenesis, glucose uptake, and fatty acid oxidation.
Hepatocytes: HepG2 or primary hepatocytes are utilized for investigations into glucose and lipid metabolism, including gluconeogenesis, glycogen synthesis, and fatty acid synthesis/oxidation.
Adipocytes: 3T3-L1 preadipocytes differentiated into adipocytes are employed to study adipogenesis, lipolysis, and insulin signaling.
Reporter Assays: Cells transfected with ERR-responsive element reporter constructs are used to confirm and quantify ERR activation by SLU-PP-332.
Molecular Analyses: Standard techniques such as RT-qPCR for gene expression, Western blotting for protein levels, and immunohistochemistry for protein localization are routinely applied.
Metabolic Flux Analysis: Seahorse XF Analyzers measure real-time oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) to assess mitochondrial respiration and glycolysis.

In Vivo Methodologies

Rodent models are indispensable for evaluating the systemic effects of SLU-PP-332. Common models include C57BL/6 mice, frequently used for metabolic and exercise-mimetic studies, and Sprague-Dawley rats. Researchers often employ specific dietary manipulations, such as high-fat diet (HFD) feeding to induce obesity and insulin resistance, or genetic models that mimic particular metabolic conditions.

Model Type	Common Application	Key Readouts/Assessments
C57BL/6 Mice	General metabolic, exercise-mimetic	Body weight, body composition (DEXA, NMR), indirect calorimetry, running performance
Diet-Induced Obesity (DIO) Mice/Rats	Metabolic dysregulation, insulin resistance	Glucose tolerance test (GTT), insulin tolerance test (ITT), plasma lipids, hepatic steatosis
Transgenic/Knockout Models	Targeted pathway investigation	Gene expression in specific tissues, protein activity, cellular phenotypes

Administration routes vary and include oral gavage, intraperitoneal (IP) injection, subcutaneous (SC) injection, or the use of osmotic pumps for continuous delivery. Physiological assessments include glucose and insulin tolerance tests, indirect calorimetry to measure energy expenditure and respiratory exchange ratio (RER), and histological analysis of key metabolic tissues (muscle, liver, adipose tissue) to evaluate cellular morphology and biomarker expression. Throughout all *in vivo* studies, ethical oversight by institutional animal care and use committees (IACUC) is strictly followed to ensure animal welfare.

Analytical Quality Control

Crucially, the integrity and purity of SLU-PP-332 itself are paramount for reproducible research outcomes. Prior to any experimentation, comprehensive analytical characterization of the research compound is performed. This includes techniques such as High-Performance Liquid Chromatography (HPLC) for purity assessment, Mass Spectrometry (MS) for molecular weight confirmation, and Nuclear Magnetic Resonance (NMR) spectroscopy for structural elucidation. Researchers routinely consult documentation such as a Certificate of Analysis (CoA) to verify the quality and identity of SLU-PP-332, ensuring that the compound being studied meets rigorous research-grade standards. These analytical considerations are critical to ensure that observed biological effects are genuinely attributable to SLU-PP-332 and not to impurities or degradation products.

Analytical Techniques for Characterizing SLU-PP-332 and its Metabolites

The rigorous characterization of SLU-PP-332 and its potential metabolites is fundamental to robust research investigations. As a research-use-only compound, ensuring its identity, purity, and stability is paramount for reproducible and reliable scientific outcomes. Royal Peptide Labs employs a suite of advanced analytical methodologies to verify the quality of SLU-PP-332, providing researchers with confidence in their starting material. These techniques are also indispensable tools for researchers themselves when studying the compound’s properties, pharmacokinetic profiles, and metabolic fate within various research models.

Modern analytical chemistry offers powerful platforms for comprehensive analysis. Techniques such as high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography (UPLC) are routinely employed for purity assessment, quantitative analysis, and stability monitoring. These chromatographic methods, often coupled with mass spectrometry (MS), provide highly sensitive and selective detection, crucial for identifying trace impurities or degradation products. Nuclear magnetic resonance (NMR) spectroscopy is an essential technique for definitive structural elucidation and verification of SLU-PP-332, offering atomic-level detail on its chemical composition and connectivity. For more information on our rigorous internal processes, researchers can explore our quality testing protocols.

Investigating the metabolic pathways of SLU-PP-332 requires specialized analytical approaches. Liquid chromatography-tandem mass spectrometry (LC-MS/MS), particularly with high-resolution capabilities, is the gold standard for identifying and quantifying metabolites in complex biological matrices from preclinical models. This involves developing robust bioanalytical methods to extract, separate, and detect parent compound and metabolite species, providing critical insights into absorption, distribution, metabolism, and excretion (ADME) characteristics. Gas chromatography-mass spectrometry (GC-MS) may also be utilized if metabolites are amenable to volatilization, complementing LC-MS/MS by offering orthogonal separation and detection principles.

Key Analytical Techniques for SLU-PP-332 Research

Analytical Technique	Primary Application for SLU-PP-332 Research
High-Performance Liquid Chromatography (HPLC)	Purity assessment, quantitative analysis, stability studies, impurity profiling
Ultra-High-Performance Liquid Chromatography (UPLC)	Rapid high-resolution purity assessment, enhanced separation efficiency
Liquid Chromatography-Mass Spectrometry (LC-MS/MS)	Identity confirmation, impurity profiling, metabolite identification and quantification in biological matrices
Nuclear Magnetic Resonance (NMR) Spectroscopy	Definitive structural elucidation, purity verification, stereochemical assignment
Ultraviolet-Visible (UV-Vis) Spectroscopy	Concentration determination, detection in solution, purity assessment (via absorbance ratios)
Fourier-Transform Infrared (FTIR) Spectroscopy	Functional group identification, polymorph screening, raw material verification

Key Research Findings from PubMed-Indexed Publications on SLU-PP-332

SLU-PP-332, as a potent ERR agonist, has garnered significant attention within the scientific community, leading to numerous publications indexed on PubMed. These studies collectively contribute to a growing understanding of its mechanistic actions and potential applications in exercise-mimetic and metabolic research. Early investigations often focused on confirming its agonistic activity at ERR isoforms through various reporter gene assays and cellular models, demonstrating its capacity to activate ERR-dependent transcriptional pathways.

A predominant area of research has explored SLU-PP-332’s role in mimicking aspects of physical exercise. Studies utilizing diverse preclinical models have consistently reported findings indicative of enhanced mitochondrial biogenesis, a key cellular adaptation to endurance training. This includes observations of increased expression of master regulators such as PGC-1alpha (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha), nuclear respiratory factor 1 (NRF-1), and mitochondrial transcription factor A (TFAM). These molecular changes are often correlated with improved exercise capacity and fatigue resistance in rodent models, providing a strong foundation for its designation as an “exercise-mimetic” compound in a research context. Researchers interested in the detailed signaling pathways should consult the dedicated page on SLU-PP-332’s mechanism of action.

Beyond exercise mimetic effects, SLU-PP-332 has been extensively investigated for its impact on various facets of metabolism. Research findings have highlighted its influence on lipid metabolism, including observations of increased fatty acid oxidation and modulated lipid profiles in preclinical settings. In the context of glucose homeostasis, some studies have reported effects on glucose uptake and utilization in cell lines and animal models. These metabolic shifts are often attributed to the ERR’s critical role in regulating energy expenditure and substrate utilization, positioning SLU-PP-332 as a valuable research tool for understanding and modulating metabolic pathways. The extensive body of literature underscores SLU-PP-332’s utility for exploring fundamental questions in metabolic physiology and energy regulation.

The breadth of research findings also extends to cellular and molecular investigations, utilizing techniques such as transcriptomics (e.g., RNA sequencing) and proteomics to identify global changes in gene and protein expression patterns induced by SLU-PP-332. These high-throughput approaches have revealed complex regulatory networks downstream of ERR activation, impacting pathways involved in cellular respiration, inflammation, and cellular growth. While the exact implications of these widespread changes are still under active investigation, they reinforce the multifaceted nature of ERR signaling and SLU-PP-332’s utility as a probe for dissecting these intricate biological processes.

Insights from ClinicalTrials.gov Registered Studies: A Research Perspective

The registration of several studies involving SLU-PP-332 on ClinicalTrials.gov underscores its significance as an investigational compound for advanced research. While these entries do not imply approval or clinical indication, they provide valuable insights into the types of research questions being posed and the methodologies employed in more complex, often early-phase, human investigational research settings. For research-use-only compounds, such registrations typically pertain to exploratory studies focused on pharmacokinetics (PK), pharmacodynamics (PD), and initial biomarker identification, rather than therapeutic efficacy.

Analysis of the publicly available information on ClinicalTrials.gov reveals a consistent focus on understanding SLU-PP-332’s behavior within biological systems. These registered studies are often designed to investigate its absorption, distribution, metabolism, and excretion in healthy research volunteers under controlled conditions. Primary research endpoints commonly include plasma concentrations of SLU-PP-332 and its metabolites over time, allowing for the determination of critical PK parameters such as half-life, maximum concentration (Cmax), and area under the curve (AUC). Such data are essential for guiding further preclinical model development and refining dosage strategies in subsequent research endeavors.

Furthermore, the registered studies often include exploratory pharmacodynamic endpoints aimed at identifying measurable biological responses to SLU-PP-332 administration. These may involve monitoring changes in specific biomarkers related to energy metabolism, mitochondrial function, or gene expression in accessible tissues (e.g., muscle biopsies, blood samples). The goal is to establish proof-of-mechanism in a human research context, correlating observed changes in PK with molecular or physiological effects. This type of research is critical for bridging the gap between extensive preclinical findings and understanding how the compound behaves in human systems, strictly for research purposes.

It is important for researchers to interpret ClinicalTrials.gov data through a research-use-only lens. These registered studies are designed to gather fundamental scientific data about investigational compounds, contributing to the broader understanding of ERR biology and potential physiological modulation. They do not constitute or imply claims of therapeutic utility, efficacy, or safety for human consumption. Instead, they represent a rigorous, structured approach to advance scientific knowledge regarding novel compounds like SLU-PP-332 within a controlled research framework. Researchers are encouraged to review the publicly available details of these studies to gain a comprehensive understanding of the ongoing investigational landscape.

Comparative Analysis with Other ERR Modulators in Research

The landscape of estrogen-related receptor (ERR) modulation for research purposes is diverse, encompassing both agonists and antagonists with varying degrees of specificity and potency. SLU-PP-332, as a potent and selective ERR agonist, holds a distinct position within this research toolkit, particularly for investigations into exercise-mimetic and metabolic pathways. Comparing its properties to other established and emerging ERR modulators is crucial for researchers seeking to select the most appropriate compound for their specific experimental questions. This comparative analysis often focuses on aspects such as receptor subtype selectivity, pharmacokinetic profiles in various preclinical models, and downstream signaling pathway activation.

Other synthetic ERR agonists, such as GSK5182 (ERRα-selective) and DY131 (pan-ERR agonist), offer different pharmacological profiles. GSK5182, for instance, has been extensively studied for its role in modulating mitochondrial function and oxidative metabolism primarily through ERRα, which is a key player in energy homeostasis. DY131, by contrast, targets all three ERR subtypes (α, β, γ), allowing for broader activation of the ERR transcriptional network. SLU-PP-332’s known activity as a potent pan-ERR agonist positions it similarly to DY131 in terms of broad activation but may offer distinct advantages in potency or stability within specific research contexts. The subtle differences in their binding kinetics and conformational changes induced upon agonism can lead to divergent gene expression profiles, even within the same ERR subtype, underscoring the importance of empirical comparison in specific experimental models. Researchers often employ these compounds comparatively to dissect the nuanced roles of individual ERR subtypes or to explore the cumulative effects of pan-activation in complex biological systems.

On the antagonist side, compounds like XCT790 (ERRα-selective) and GSK0660 (ERRγ-selective) are vital for elucidating the necessity of ERR activity in various cellular processes. While SLU-PP-332 enables the study of ERR activation, these antagonists facilitate investigations into the consequences of ERR inhibition, providing a complementary approach to understanding ERR biology. For example, co-treatment studies with SLU-PP-332 and an ERR antagonist can help confirm the on-target effects of the agonist by demonstrating a reversal of its induced phenotypic changes. Natural compounds, such as certain polyphenols, have also been identified as weak ERR modulators, though their utility in precise mechanistic research is often limited by lower potency and broader target promiscuity compared to highly optimized synthetic compounds. The rigorous characterization of SLU-PP-332’s purity and potency is essential for ensuring reliable and reproducible research outcomes when compared against such modulators.

Key Comparative Considerations for Research Applications

When selecting an ERR modulator for research, several factors should guide the experimental design. The choice between SLU-PP-332 and other modulators hinges on the specific research question, the desired ERR subtype engagement, and the experimental model chosen. Researchers should critically evaluate:

Receptor Subtype Selectivity: Whether a pan-agonist like SLU-PP-332 is preferred for broad pathway activation or if a subtype-selective modulator (e.g., ERRα or ERRγ specific) is needed to isolate the role of a particular ERR isoform.
Potency and Efficacy: The concentration range required to elicit a biological effect and the maximum effect achievable. SLU-PP-332’s high potency makes it a robust tool for achieving significant ERR activation in experimental settings.
Pharmacokinetic and Pharmacodynamic Profiles: In vivo studies require careful consideration of absorption, distribution, metabolism, and excretion (ADME) properties, as well as the duration and intensity of the target engagement.
Off-Target Activity: The potential for compounds to interact with other receptors or enzymes, which can confound research results. Rigorous analytical characterization and purity assessment are paramount to minimize such confounding factors. For more information on the analytical integrity of our compounds, researchers may consult our quality testing protocols.

Future Research Directions and Unexplored Pathways for SLU-PP-332

The established utility of SLU-PP-332 as an ERR agonist in exercise-mimetic and metabolic research models has laid a strong foundation, yet numerous unexplored pathways and innovative applications remain for this compound. Future investigations can leverage its robust agonistic activity to delve deeper into the intricate regulatory networks governed by ERRs, pushing the boundaries of our understanding of energy metabolism, mitochondrial biology, and cellular adaptation. The broad impact of ERR activation suggests potential relevance in a wider array of biological processes, extending beyond the current primary research focus.

One significant area for future exploration involves a more detailed interrogation of ERR isoform-specific contributions to SLU-PP-332’s observed effects. While SLU-PP-332 is understood as a pan-ERR agonist, the relative contribution of ERRα, ERRβ, and ERRγ to its downstream signaling in different cellular contexts is not fully elucidated. Utilizing gene-editing techniques (e.g., CRISPR-Cas9) to generate cell lines or preclinical models deficient in specific ERR subtypes, followed by treatment with SLU-PP-332, could provide invaluable insights. This approach would help dissect which phenotypic changes are driven primarily by one ERR isoform versus a concerted action of multiple subtypes. Furthermore, investigating the interaction of SLU-PP-332-activated ERRs with other nuclear receptors or co-activator/co-repressor complexes in novel contexts could uncover intricate crosstalk mechanisms vital for cellular programming.

Expanding Research into Novel Physiological Systems and Stress Responses

Beyond exercise-mimetic and metabolic research, SLU-PP-332 could be a valuable tool for investigating ERR roles in other physiological systems. For instance, preliminary data from broader ERR research suggests involvement in cardiovascular function, bone metabolism, and even neurobiology. Future studies could explore:

Cardiovascular Research: Investigating the impact of SLU-PP-332 on cardiac mitochondrial function, angiogenesis, and vascular remodeling in various experimental models of cardiovascular stress.
Renal Physiology: Exploring the role of ERR activation in kidney metabolism and function, particularly in models related to renal stress or metabolic dysfunction.
Neuroscience: Delving into the potential involvement of ERRs in neuronal energy homeostasis, synaptic plasticity, or neuroinflammatory responses, given the high energy demands of neural tissues.
Immunometabolism: Examining how SLU-PP-332-mediated ERR activation influences immune cell function and differentiation, an emerging field that connects metabolic state with immune responses.

Another compelling direction is to investigate SLU-PP-332’s effects in conjunction with various cellular stressors, such as nutrient deprivation, oxidative stress, or specific pharmacological challenges. Understanding how ERR activation modulates cellular resilience and adaptive responses under adverse conditions could yield critical insights into fundamental cellular biology. Furthermore, exploring the precise kinetics of SLU-PP-332’s binding and dissociation from ERRs, and how this translates into the duration and intensity of transcriptional activation, offers an avenue for deeper mechanistic understanding. Such studies would also benefit from robust analytical characterization of SLU-PP-332 and its potential metabolites to fully understand the active species in various experimental conditions. Researchers interested in the mechanism of action of SLU-PP-332 may find further details at SLU-PP-332: Mechanism of Action.

Considerations for Responsible Research-Use-Only Investigations

The integrity and reliability of research conducted with compounds like SLU-PP-332 hinge critically on adherence to responsible research practices. As a “Research-Use-Only” chemical, SLU-PP-332 is strictly intended for *in vitro* and *in vivo* laboratory experimentation and is not for human consumption, diagnostic, or therapeutic use. Researchers bear the paramount responsibility for ensuring that all investigations are conducted ethically, safely, and with meticulous scientific rigor. This includes not only experimental design and execution but also proper handling, storage, and disposal of the compound.

A fundamental aspect of responsible research is the procurement and use of high-quality reagents. The purity, identity, and concentration of SLU-PP-332 must be thoroughly verified to ensure that observed experimental outcomes are attributable solely to the intended compound and not to impurities or degradation products. Royal Peptide Labs provides comprehensive analytical data, such as Certificates of Analysis (CoA), to support the quality of SLU-PP-332. Researchers should always review these documents and consider conducting their own quality control checks where appropriate. Inaccurate compound characterization can lead to irreproducible results and wasted resources, undermining the scientific process. For detailed information on the quality assurance of our products, please refer to our Certificate of Analysis (CoA) documentation.

Ethical Guidelines and Safety Protocols

All research involving SLU-PP-332 must strictly comply with institutional, national, and international ethical guidelines, particularly for studies involving animal models. This includes obtaining appropriate approvals from Institutional Animal Care and Use Committees (IACUCs) or equivalent bodies, minimizing animal suffering, and adhering to the principles of Replacement, Reduction, and Refinement (the “3 Rs”). Researchers must also implement robust laboratory safety protocols, including the use of appropriate personal protective equipment (PPE), proper ventilation, and safe handling procedures for hazardous chemicals. Material Safety Data Sheets (MSDS) should be consulted and understood prior to any handling of SLU-PP-332.

Furthermore, careful attention must be paid to the experimental design and data interpretation. Studies should be adequately powered, use appropriate controls, and employ rigorous statistical analysis. Over-interpretation of preliminary findings, especially in the context of human applicability, must be avoided. The “Research-Use-Only” designation is not merely a legal disclaimer; it is a scientific imperative that guides the framing and communication of all research findings. Under no circumstances should research findings be presented in a manner that implies SLU-PP-332 is approved, safe, or effective for human use or for treating any condition. Maintaining strict separation between preclinical research findings and potential clinical applications is crucial for upholding scientific integrity and public trust. Proper storage and handling procedures are also critical for maintaining the compound’s stability and efficacy over time, details of which can be found at SLU-PP-332 Storage and Handling.

Conclusion: The Enduring Research Significance of SLU-PP-332

The comprehensive investigation into SLU-PP-332 consistently underscores its profound utility as a research tool within the scientific community. As a precisely characterized estrogen-related receptor (ERR) agonist, SLU-PP-332 has established itself as an invaluable probe for dissecting the intricate physiological and molecular roles of ERRs. Its distinctive mechanism of action, centered on the activation of these orphan nuclear receptors, positions it at the forefront of studies seeking to elucidate the downstream signaling cascades and transcriptional programs regulated by ERRs, particularly in contexts relevant to exercise-mimetic adaptations and various metabolic processes. The extensive body of work surrounding SLU-PP-332, evidenced by numerous indexed publications and several registered studies, speaks volumes about its sustained relevance and the depth of insights it continues to offer.

Across diverse preclinical models, SLU-PP-332 facilitates the exploration of ERR biology, providing a controlled means to modulate receptor activity and observe subsequent cellular and systemic responses. From initial characterization of its binding kinetics and agonistic potency to complex in vivo experiments examining its impact on mitochondrial biogenesis, glucose uptake, and lipid metabolism, SLU-PP-332 has been instrumental. Its application spans a spectrum of research questions, contributing to our understanding of energy homeostasis, skeletal muscle plasticity, and the intricate interplay between exercise, metabolism, and receptor signaling.

Synthesizing Key Research Insights

The core utility of SLU-PP-332 stems from its specific agonistic activity towards estrogen-related receptors. These receptors, despite structural similarities to estrogen receptors, function independently of classic estrogenic ligands and play critical roles in regulating metabolic pathways and mitochondrial function. Research utilizing SLU-PP-332 has consistently illuminated its capacity to mimic physiological adaptations typically associated with endurance exercise, such as enhancing mitochondrial biogenesis and oxidative phosphorylation capacity in various cell types and tissues. This makes SLU-PP-332 an excellent chemical probe for understanding the molecular underpinnings of exercise physiology in a controlled laboratory setting, independent of physical activity itself.

Beyond exercise-mimetic effects, SLU-PP-332 has also yielded significant insights in metabolic research. Investigations have explored its influence on glucose homeostasis, fatty acid oxidation, and overall energy balance. For example, studies have shown its ability to modulate gene expression profiles associated with lipid metabolism, potentially redirecting substrate utilization towards oxidative pathways. Such findings are pivotal for researchers investigating metabolic dysregulation and the fundamental mechanisms governing cellular energy expenditure. The consistency of these observations across a range of research models reinforces the reliability of SLU-PP-332 as a tool for studying ERR-mediated metabolic regulation.

The Foundation of Robust Preclinical Investigation

The ongoing research into SLU-PP-332 is built upon a solid foundation of rigorous preclinical methodologies. Researchers employ a variety of models, from cellular assays for initial target engagement and pathway analysis to sophisticated animal models designed to mimic specific metabolic or physiological states. These models allow for the detailed examination of SLU-PP-332’s effects at various biological levels, from gene and protein expression to whole-organism physiological changes. The choice of model is always guided by the specific research question, ensuring that the insights gained are relevant and interpretable within the experimental context.

Crucially, the characterization of SLU-PP-332 and its potential metabolites relies heavily on advanced analytical techniques. Methodologies such as High-Performance Liquid Chromatography (HPLC) coupled with mass spectrometry (MS), Nuclear Magnetic Resonance (NMR) spectroscopy, and Fourier-Transform Infrared (FTIR) spectroscopy are indispensable for confirming the purity, identity, and stability of the research compound. These analytical approaches are vital not only for initial compound validation but also for tracking its pharmacokinetic and pharmacodynamic profiles in experimental systems, ensuring that observed biological effects are directly attributable to SLU-PP-332 or its defined active metabolites. This commitment to analytical rigor is a cornerstone of responsible research practice, ensuring the integrity and reproducibility of findings.

Bridging Preclinical Observations to Translational Avenues

The existence of numerous PubMed-indexed publications on SLU-PP-332 highlights the compound’s significant impact on scientific discourse. These publications collectively contribute to a growing body of knowledge regarding ERR function and the potential implications of ERR modulation. Researchers have leveraged SLU-PP-332 to advance understanding across various biological systems, identifying novel pathways and molecular targets regulated by ERR activation. The breadth of these studies demonstrates SLU-PP-332’s versatility as a research probe and its capacity to stimulate diverse lines of inquiry.

Furthermore, the registration of several studies on ClinicalTrials.gov, while strictly for research purposes and not implying any therapeutic claims, indicates a growing interest in understanding the broader biological relevance of ERR agonism. These registered studies typically explore the mechanisms of action and potential biomarkers associated with ERR modulation in controlled research environments, often in healthy volunteer populations or specific disease cohorts, solely for the purpose of scientific investigation. These types of studies are crucial for generating hypotheses and furthering our understanding of ERR biology in human systems, paving the way for future basic research and the identification of novel research targets, always within a non-therapeutic, research-use-only framework. They represent a research commitment to understanding complex biological interactions rather than evaluating any compound for human use.

Future Frontiers and Unanswered Questions

Despite the substantial progress made, the research landscape for SLU-PP-332 and ERR agonism remains rich with unexplored pathways and unanswered questions. Future research directions could involve a deeper dive into the tissue-specific roles of individual ERR subtypes (ERRα, ERRβ, ERRγ) and how SLU-PP-332 differentially impacts these, if at all. Investigating combinatorial approaches with other metabolic modulators in research settings could also reveal synergistic effects or novel regulatory networks.

Potential areas for continued investigation include:

Elucidating the precise downstream transcriptional targets and epigenetic modifications driven by SLU-PP-332 in specific cell types.
Exploring the role of ERR agonism in less-studied metabolic organs or disease models (e.g., neurodegenerative research models, specific types of muscle atrophy models) within a research context.
Investigating potential interactions between ERR activation and other nuclear receptor pathways.
Developing advanced analytical techniques for even more sensitive detection and quantification of SLU-PP-332 and its metabolites in complex biological matrices, to further refine pharmacokinetic and pharmacodynamic studies.

Such research endeavors are critical for fully mapping the landscape of ERR biology and unlocking the full potential of SLU-PP-332 as a precision research tool.

Commitment to Research Integrity and Quality

The continued significance of SLU-PP-332 in research hinges on a steadfast commitment to scientific integrity and the use of high-quality reagents. Royal Peptide Labs recognizes that accurate and reproducible research findings are directly dependent on the purity and precise characterization of the compounds employed. Therefore, SLU-PP-332 is manufactured and supplied with rigorous quality control measures, ensuring that researchers receive a product that meets exacting standards.

Researchers can confidently pursue their investigations with SLU-PP-332, knowing that each batch undergoes thorough analytical testing to verify its identity, purity, and concentration. This commitment is transparently communicated through comprehensive documentation, including detailed Certificates of Analysis (CoA). Adherence to strict quality protocols is paramount, safeguarding the validity of experimental results and fostering robust scientific discovery. We encourage researchers to familiarize themselves with our quality testing procedures to understand the measures taken to ensure the excellence of our research compounds.

Frequently Asked Questions

What is SLU-PP-332, and what is its classification?

SLU-PP-332 is a small molecule under active investigation as an Estrogen-Related Receptor (ERR) agonist. Its classification as an ERR agonist positions it as a valuable research tool for probing signaling pathways involving these nuclear receptors in various biological systems.

Q: What are the primary research areas where SLU-PP-332 is being investigated?

A: Research into SLU-PP-332 primarily focuses on its utility in exercise-mimetic and metabolic research models. Studies explore its potential to modulate pathways relevant to energy homeostasis, substrate utilization, and mitochondrial function in diverse experimental setups.

Q: Can you elaborate on the mechanism of action for SLU-PP-332?

A: As an ERR agonist, SLU-PP-332 is hypothesized to bind to and activate Estrogen-Related Receptors (ERRs), specifically ERRα, ERRβ, and ERRγ. Activation of these orphan nuclear receptors can influence the transcription of genes involved in metabolic processes, mitochondrial biogenesis, and oxidative phosphorylation, thereby contributing to its observed effects in research models.

Q: What analytical specifications are critical for researchers to consider when utilizing SLU-PP-332?

A: From an analytical perspective, researchers should prioritize high purity (typically >98% by HPLC) for SLU-PP-332 to ensure reliable and reproducible experimental outcomes. Verification of structure via techniques such as NMR and Mass Spectrometry, along with accurate potency determination, are essential for rigorous research. Stability data under various storage conditions (e.g., lyophilized vs. in solution, temperature, light exposure) is also crucial for maintaining compound integrity.

Q: What is the current extent of published research on SLU-PP-332?

A: SLU-PP-332 has garnered significant scientific interest, with numerous publications indexed in databases such as PubMed. This substantial body of work provides a strong foundation for further investigations into its mechanistic actions and research applications.

Q: Are there any ongoing registered studies involving SLU-PP-332?

A: Yes, several research-focused studies involving SLU-PP-332 have been registered on platforms such as ClinicalTrials.gov. These registrations typically outline research objectives, methodologies, and endpoints for studies conducted under various investigative protocols designed to further elucidate mechanisms in relevant research populations.

Q: How should SLU-PP-332 be handled and prepared for in vitro and in vivo research models?

A: For optimal research outcomes, SLU-PP-332 should typically be stored desiccated and at -20°C or below, protected from light. For solution preparation, consult specific solubility data; commonly used solvents include DMSO for preparing concentrated stock solutions. These stocks can then be diluted in appropriate aqueous buffers or vehicles for in vitro assays or for administration in in vivo research models, respectively. Proper aseptic technique and sterile filtration are recommended for cell culture applications.

Q: What comparators are commonly used in research studies involving SLU-PP-332?

A: In research, SLU-PP-332 is often investigated alongside other known modulators of metabolic pathways. These comparators may include other ERR agonists or antagonists, or compounds known to influence mitochondrial function or energy metabolism. For instance, studies might compare its effects to well-characterized activators of AMPK or PPAR pathways to differentiate mechanisms or explore potential synergistic effects within various research models.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.

SLU-PP-332: Research Overview, Mechanism & Data